Yu Heng Pharmaceutical: The acquisition of new drugs in the research product line to further strengthen

The company announces the use of super raise funds 65 million yuan for the purchase of compound SX004 and its derivative drugs for the United States DI-Nepal patent actual ownership. Tyrosine kinase inhibitor is a hotspot of antitumor drugs research and development of SX004 compounds and their derivative drugs the United States is a new generation of multiple target tyrosine kinase inhibitors. The methadone drug has basically completed preclinical experimental research and is about to apply to the National Bureau for Clinical approvals.　　Multi-target tyrosine kinase inhibitors are molecular targeted antitumor agents, and more and more tyrosine kinase inhibition (such as imatinib, gefitinib, etc.) has been successfully developed and approved for clinical use, and has yielded encouraging results and sales. Product line to further strengthen the company's development potential of the project acquisition further strengthen the company's product line, but also in line with the company's current product line strategic layout. At present, the MED-02 and MED-08 are also in the field of anti-tumor with great potential.　　The company has now perfected its own research and development system, the current strategy is mainly through the acquisition of projects quickly set up their own product line. Earnings forecasts and investment ratings we believe that the company has become a superior and even the great potential of pharmaceutical listed companies, optimistic about the long-term development of the company.　　We hold the forecast unchanged for the time being, we expect to realize EPS1.40 yuan, 2.13 yuan and 2.95 yuan respectively in 10-12 years, to maintain the "buy" investment rating. Risk tips in the development of new drugs progress below the expected risk.